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Abstract 
The primary purpose of this study was to process partially hydrolyzed PVOH grades (degree 
of hydroxylation (DH): 33-88%) via HME and to evaluate them as carrier for oral immediate 
release dosage forms in order to improve the release rate of poorly water soluble drugs (i.e. 
HCT and CEL) via the formulation of solid dispersions. PVOH grades (DH > 70%) were able 
to solubilize HCT and CEL up to 15%, but required higher extrusion temperature, due to the 
crystalline nature of PVOH. The highest drug release rate was observed from hot-melt 
extruded PVOH samples with a high DH. While drug release from extrudates consisting of 
PVOH with a low DH was affected by ionic strength, there was no influence of pH and ionic 
strength on HCT release from PVOH samples with a higher DH. However, PVOH (DH > 
70%) required higher extrusion temperatures, which could hamper its application for 
thermosensitive drugs. Therefore, the secondary purpose was to investigate the effect of 
sorbitol, a water-soluble plasticizer, on the thermal properties of hot-melt extruded PVOH 
(DH > 70%). The melting of PVOH/sorbitol mixture was required to establish molecular 
interactions between PVOH and sorbitol. These molecular interactions were reflected in the 
HME behavior: whereas an extrusion temperature of 180°C was necessary to process 
physical mixtures of PVOH (DH > 70%) and sorbitol, only 140°C was necessary during re-
extrusion (after quench cooling and cryomilling) of the PVOH/sorbitol mixture. In addition, the 
in vitro and in vivo dug release of plasticized PVOH was examined; whereas the 
CEL/PVOH/sorbitol system was able to maintain supersaturation during in vitro dissolution 
(0.1 N HCl) compared to Celebrex®, the in vivo pharmacokinetic parameters (AUC0-24h, Cmax 
and Tmax) were highly comparable. 
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1 INTRODUCTION 
The number of New Chemical Entities (NCE) which are classified as class II or IV drugs 
according to the Biopharmaceutical Classification System (BCS) have increased over the last 
decade (Nkansah et al., 2013). Class II and IV drugs are characterized by low oral 
bioavailability, mainly due to their poor aqueous solubility. Therefore, several techniques to 
improve solubility of poorly water-soluble drugs have been developed: inclusion complexes in 
cyclodextrins (Joudieh et al., 2009), self-emulsifying drug delivery systems (Porter et al., 
2008), nanocrystals (Junghanns and Muller, 2008; Shegokar and Muller, 2010), coacervation 
(De Jaeghere et al., 2013), solid dispersions (Janssens and Van den Mooter, 2009). The 
latter technique (where the drug is (molecularly) dispersed in a carrier) can be prepared via 
solvent evaporation (Dave et al., 2012), fusion methods (Gorajana et al., 2013), 
complexation (Taupitz et al., 2013), spray-drying (Jang et al., 2013) or hot-melt extrusion 
(Mohammed et al., 2012). For pharmaceutical applications hot-melt extrusion (HME) is 
considered an effective process to formulate immediate release forms of poorly water-soluble 
drugs via the formation of solid dispersions or solutions since it has many advantages over 
conventional approaches, such as a solvent-free process, the possibility to be operated as 
continuous process, a limited number of processing steps (Maniruzzaman et al., 2013; 
Repka et al., 2012). Several water-soluble polymeric carriers suitable for HME applications 
have been identified (e.g. hydroxypropyl cellulose, polyethylene oxide, poly(vinyl pyrrolidone) 
(Crowley et al., 2007), polyvinyl alcohol (Dawson and Stevens, 2002)).  
Partially hydrolyzed polyvinyl alcohol (PVOH), used for pharmaceutical applications, is a 
copolymer of vinyl acetate and vinyl alcohol, and is synthesized by polymerization of vinyl 
acetate followed by partial hydrolysis (in the presence of aqueous sodium hydroxide) to 
substitute part of the acetate groups on the polymer backbone by a hydroxyl function. The 
synthesis conditions (i.e. catalyst concentration, reaction temperature and time) determine 
the degree of hydroxylation of PVOH (typically the content varies between 30 and 99 mol%) 
and molecular weight, which both influence the water solubility (Hallensleben, 2000). Its 
hydrophilic, non-toxic (DeMerlis and Schoneker, 2003), non-carcinogenic and biodegradable 
(Thellen et al., 2013) properties make partially hydrolyzed PVOH an interesting polymer for 
pharmaceutical applications and it is currently used as stabilizing agent in emulsions, 
viscosity-increasing agent in ophthalmic formulations and for lubrication purposes in artificial 
tears (Rowe et al., 2006).  
The primary purpose of this study was to process different partially hydrolyzed PVOH grades 
via HME and to evaluate them as carrier for oral immediate-release dosage forms in order to 
improve the release rate of poorly water-soluble drugs (i.e. hydrochlorothiazide (HCT) and 
celecoxib (CEL)) via the formulation of solid dispersions. A secondary purpose was to 
investigate the effect of a water-soluble plasticizer (i.e. sorbitol) on the thermal properties of 
hot-melt extruded PVOH. In addition, the in vitro and in vivo drug release of plasticized 
PVOH was examined.  
 
 
 
 
 
 
 
 
 
 
 
 2 MATERIALS AND METHODS 
2.1 Materials 
Several PVOH grades (obtained from Kuraray, Hattersheim am Main, Germany) with varying 
degrees of hydrolysis were evaluated: type LM 25 (33-38% hydrolyzed), type LM 22 (47-53% 
hydrolyzed), type 505 (72-75% hydrolyzed). In addition, a pharmaceutical PVOH grade (type 
4-88, 88% hydrolyzed, provided by Merck, Darmstadt, Germany) was included in the study. 
The LM-grades were end group-modified with carboxylic acid to provide good aqueous 
dispersibility. Hydrochlorothiazide (HCT) (Utag, Amsterdam, Netherlands), a BCS class III 
drug (Wu and Benet, 2005), and celecoxib (CEL) (Sanico, Turnhout, Belgium), a BCS class II 
drug (Turner et al., 2012), were used as model drugs. Sorbitol (Fagron, Waregem, Belgium) 
was used as water-soluble plasticizer of PVOH. 
 
2.2 Hot-melt extrusion  
Pure PVOH, mixtures of PVOH/HCT and mixtures of PVOH/sorbitol were processed using a 
co-rotating, fully intermeshing twin screw extruder (Prism Eurolab 16, Thermo Fisher, 
Germany), operating at a screw speed of 100 rpm and processing temperatures of 130-
180°C. The extruder was equipped with a gravimetric feeder, two Archimedes screws with 3 
mixing zones and a cylindrical die of 3 mm. Afterwards, the extrudates were either manually 
cut using surgical blades into mini-tablets of 2 mm length or quench-cooled in liquid nitrogen, 
cryomilled and sieved through a 300 micron sieve. 
Mixtures of cryomilled PVOH/sorbitol extrudate (<300µm) and CEL were processed using a 
co-rotating twin screw extruder (Haake MiniLab II Micro Compounder, Thermo Electron, 
Karlsruhe, Germany), operating at a screw speed of 60 rpm and a processing temperature of 
140°C. The extruder was equipped with a pneumatic feeder, two Archimedes screws and a 2 
mm cylindrical die. The extrudates were quench-cooled in liquid nitrogen, cryomilled and 
sieved through a 300-micron sieve. 
2.3 Characterization 
2.3.1 Thermal analysis 
Thermogravimetric analysis (Hi-res TGA 2950, TA instruments, Leatherhead, UK) was 
employed to investigate the thermal stability of the different PVOH grades. Samples (± 15 
mg) were equilibrated at 25°C and heated to 600 °C at a heating rate of 10°C/min while 
recording the weight loss. 
Glass transition temperature (Tg), crystallization temperature (Tc), melting point (Tm) of pure 
components, extruded and cryomilled samples were analyzed by differential scanning 
calorimetry (DSC), using a Q2000 DSC (TA Instruments, Leatherhead, UK) equipped with a 
refrigerated cooling system. Dry nitrogen at a flow rate of 50 ml/min was used to purge the 
DSC cell. The samples, loaded in non-hermetic aluminum Tzero pans, were evaluated 
according to DSC conditions (heating rate: 10°C/min) and heat iso MDSC conditions (heating 
rate: 2°C/min, amplitude: ± 0.318 °C, period: 60 sec.) during 3 cycles (heating, cooling and 
heating) from -20 to 220°C. Measurements were performed in triplicate. All results were 
analyzed using the TA Instruments Universal Analysis 2000 software. 
The degree of relative crystallinity of PVOH  was calculated with reference to the 
enthalpy of fusion ( ) of the perfect PVOH crystal (138.6 J/g) (Mallapragada et al., 1997), 
with the following formula: , whereby  was defined as the enthalpy of 
fusion of the respective PVOH. 
2.3.2 Karl Fisher (KF) coulometric titration 
The water content of the different PVOH grades was quantified via KF coulometric titration. 
The measurements were performed with a V30 Compact Volumetric KF titrator (Mettler 
Toledo, Zaventem, Belgium). PVOH (0.5 – 1 g) was added into the reaction cell that 
contained Hydranal®-Methanol dry (Sigma-Aldrich, Germany) as solvent, and Hydranal®-
Composite 5 (1-component, Sigma-Aldrich, Germany) was used as titrant. 
2.3.3 X-ray diffraction 
The crystallinity of PVOH, HCT and CEL was investigated by means of X-ray diffraction. The 
X-ray diffraction patterns were determined using a D5000 Cu Kα diffractor (λ = 0.154 nm) 
(Siemens, Karlsruhe, Germany) with a voltage of 40 V in the angular range of 10° < 2θ < 60° 
using a step scan mode (step width = 0.02°, counting time = 1s/step). 
2.3.4 In vitro drug release 
The influence of pH and ionic strength on drug release was investigated for PVOH/HCT 
extrudates using USP apparatus 1 (baskets), in a VK 7010 dissolution system combined with 
a VK 8000 automatic sampling station (Vankel Industries, New Jersey, USA). The release 
rate from extrudates containing 15 mg HCT was tested in demineralized water, 0.1 N HCl 
(pH 1.0), dissolution media pH 7.4 with varying ionic strength (0-0.14 M) and dissolution 
media with an ionic strength of 0.14 M with varying pH (1- 9) (900 ml, at a temperature of 
37±0.5°C), while the rotational speed of the baskets was 100 rpm. Samples of 5 ml were 
withdrawn at 10, 20, 30, 40, 50, 60, 70, 80, 100 and 120 min. and spectrophotometrically 
analyzed for HCT at 272 nm by means of a Shimadzu UV-1650PC UV-VIS double beam 
spectrophotometer (Antwerp, Belgium). Each batch was evaluated in triplicate. 
The in vitro drug release of CEL was investigated for PVOH formulations containing 15 mg 
CEL formulated as physical mixture or cryomilled extrudate. CEL release from PVOH 
formulations and from a commercially available CEL formulation (Celebrex®, a capsule 
formulation containing 37.4% CEL) was determined using the same procedure as for the 
HCT formulations, but only 0.1 N HCl (pH 1.0) was used as dissolution medium. PVOH/CEL 
formulations were filled into hard-gelatin capsules prior to dissolution testing. CEL 
concentrations were spectrophotometrically analyzed at 250 nm by means of a Shimadzu 
UV-1650PC UV-VIS double beam spectrophotometer (Antwerpen, Belgium). Each batch was 
evaluated in triplicate. 
2.3.5 Bioavailability study 
The study was approved by the Ethical Committee of the Faculty of Veterinary Medicine 
(Ghent University, Belgium). A cross-over study in dogs (n = 6, body weight varying between 
10 and 15 kg) was performed to determine the bioavailability of CEL after oral administration 
of the cryomilled PVOH extrudate and Celebrex® formulation. The dogs received a hard-
gelatin capsule (n°0) containing 5 mg/kg body weight CEL, formulated as the cryomilled 
extrudate or Celebrex® formulation. The washout period between sessions was 2 weeks. 
Blood samples (2 ml) were taken prior to each treatment day (=blank sample) and 0.25, 0.5, 
1, 2, 3, 4, 6, 8, 12 and 24 h after administration by puncturing the vena jugularis. The blood 
samples were collected in dry heparinized tubes and within 1 h after collection blood was 
centrifuged for 10 min at 1500 xg and kept frozen at -20°C until analysis. 
2.3.6 Determination of celecoxib plasma concentration 
CEL plasma concentrations were determined based on the HPLC-MS method developed by 
Nkansah et al. (Nkansah et al., 2013) using indomethacin as internal standard. The 
chromatographic system consisted of an Agilent 1100 series (Agilent, Heilbronn, Germany), 
Separation was carried out using a Luna C18 column (50 mm x 2.0 mm, particle size 3 μm; 
Phenomenex, Torrance, CA). The injection volume was 5 μL. Gradient elution was 
performed with a flow rate of 0.2 ml/min starting at 50% eluent A (5 mM ammonium formate 
with 0.1% formic acid). Eluent B (acetonitrile) was linearly increased from 50% to 70% during 
3 min. The initial conditions were regained over a 0.2 min time interval, followed by a 7 min 
equilibration time prior to the next injection. This resulted in an overall run time of 10 min. 
Detection was performed using a API 3000 triple quadrupole mass spectrometer (AB Sciex, 
Framingham, MA) equipped with an electrospray ionization source in the electrospray 
negative ion mode (ESI-). Nitrogen was used as both drying and nebulizing gas. Product ions 
were detected using the multiple reaction-monitoring (MRM) mode, using argon as collision 
gas. The capillary voltage and source temperature were optimized at -4.2 kV and 300°C, 
respectively. The collision energy and cone voltage were optimized for each compound 
individually. Data were collected and processed using the Analyst software (AB Sciex, 
Framingham, MA). The peak plasma concentration (Cmax), the time to reach Cmax (Tmax), and 
the extent of absorption (AUC0-24h) were determined. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 RESULTS AND DISCUSSION 
3.1 Partially hydrolyzed PVOH 
Partially hydrolyzed PVOH was evaluated as carrier for oral immediate release applications, 
and HCT, which is stable over a wide temperature range, was chosen as model drug 
(Valladao et al., 1996). Thermal stability of partially hydrolyzed PVOH is a prerequisite for 
HME. Therefore, thermal gravimetric analysis (TGA) of the partially hydrolyzed PVOH grades 
was performed. This technique indicated a weight loss up to a temperature of 150°C which 
was linked to the presence of water in the PVOH polymer as KF titration confirmed that the 
water content of the samples ranged from 1.0 to 3.7%. The onset of thermal polymer 
degradation was detected at 240°C, indicating that PVOH polymers are stable under the 
process conditions used in the study (a maximum extrusion temperature of 180°C was 
used)(Alexy et al., 2004; Peng and Kong, 2007).  
Modulated differential scanning calorimetry (MDSC) (Fig. 1) was used to examine the 
crystalline nature of PVOH with different degree of hydrolysis (33 – 88%). The non-reversed 
heat flow of PVOH with high degree of hydrolysis (> 70%) showed two endothermic signals, 
corresponding with water evaporation and melting of PVOH. In contrast, only water 
evaporation was observed in PVOH samples with a low degree of hydrolysis (< 50%). 
Therefore, PVOH with high degree of hydroxylation (>70 %) contain a degree of crystallinity, 
due to an increased number of OH groups, which are able to form hydrogen bonds. 
Furthermore, the glass transition temperature was observed in the reversed heat flow for all 
PVOH grades, which was increased during second heating (Table 1) due to the evaporation 
of water during the first heating phase (Hassan and Peppas, 2000). 
This difference in crystallinity was also reflected in the X-ray diffraction (XRD) patterns of the 
different PVOH powders (Fig. 2): whereas a diffuse halo was observed for PVOH grades with 
a low degree of hydroxylation (due to their higher content of amorphous polyvinyl acetate), 
crystalline reflections at 2θ = 19.9° and 20.2° were detected in samples with a high degree of 
hydroxylation (Bunn, 1948). The semi-crystalline nature of these PVOH grades was 
confirmed based on the fusion enthalpy of the DSC melting peaks: 16.91.7% crystallinity for 
type 505 (72-75%) and 32.13.6% crystallinity for type 4-88 (88%), respectively. The 
correlation between crystallinity and the degree of hydroxylation is linked to intermolecular 
hydrogen bonding between the polymer chains (Assender and Windle, 1998), whereby 
PVOH grades with a high degree of hydrolysis (which contain more vinyl alcohol units), could 
recrystallize upon cooling due to hydrogen bonding. In contrast, PVOH with a low degree of 
hydrolysis (< 50%, type LM25 and LM22) did not recrystallize during cooling, as the higher 
number of vinyl acetate units disrupted hydrogen bonding between vinyl alcohols. 
The processability of PVOH formulations via HME (3 mm die) was evaluated in function of 
degree of hydroxylation and extrusion temperature. The extrusion behavior of partially 
hydrolyzed PVOH grades differed depending on their degree of hydroxylation: while type 
LM25 (33 - 38%) and LM22 (47 - 53%) were easily processable at a temperature of 100°C, 
higher temperatures (180°C) were required to process type 505 (72 – 75%) and 4-88 (88%), 
as their crystalline nature required higher temperatures for processing via HME. These 
extrusion temperatures were correlated with the DSC profiles observed for the different 
PVOH grades (Table 1). In addition, PVOH grades with a higher degree of hydroxylation had 
a higher molecular weight (Table 1), and therefore higher extrusion temperatures were 
required during the extrusion process to lower the flow viscosity of these PVOH grades.  
The X-ray diffraction patterns of HCT and physical mixtures of PVOH/HCT showed the 
crystalline nature of HCT at 2θ = 17°. After extrusion, transparent extrudates were obtained 
for up to 15% HCT content in combination with PVOH with a high degree of hydroxylation (> 
70%), no HCT crystals were detected in these samples (Fig. 3).  In contrast, even at 10% 
HCT load, formulations containing PVOH with a lower degree of hydroxylation (< 50%) were 
opaque. These PVOH grades were only able to solubilize 5% HCT.  
The influence of pH on HCT release from PVOH-based extrudates was evaluated in a pH 
range 1 to 9, using dissolution media with a constant ionic strength of 0.14M (Fig. 4). 
Although PVOH type LM25 (33 - 38%) and LM22 (47 - 53%) were chemically end modified 
with carboxylic groups, which could potentially reduce the release rate from these 
formulations at lower pH values, only the release rate from PVOH type LM 22 (47 – 53%) 
was slightly affected at pH 1. HCT release from type 505 (72-75%)- and 4-88 (88%)-based 
formulations was independent of pH. In contrast, the effect of ionic strength of the dissolution 
medium (pH 7.4) on HCT release was significant for PVOH matrices with a low degree of 
hydroxylation, while no effect on formulations containing PVOH with a higher degree of 
hydroxylation (> 70%) was detected (Fig. 5).  
The influence of drug load on drug release was investigated with formulations containing 5-
15% HCT (Fig. 6). Drug release after 120 min from 4-88 (88%) formulations containing 5 and 
15% HCT was 51% and 92%, respectively. This dependency of drug release on drug content 
was observed for all PVOH types.  As HCT is released from PVOH formulations via swelling-
controlled diffusion, upon contact of the PVOH formulations with the dissolution medium two 
phenomena will interact: swelling and true dissolution of PVOH (Colombo, 1993).  Initially, 
PVOH chains swell due to water sorption and therefore, HCT diffuses through this swollen 
rubbery region. Water sorption also induces dissolution of the polymer matrix. As water 
sorption will increase in PVOH formulations containing a higher drug load due the higher 
osmotic pressure, this will enhance polymer swelling, PVOH dissolution and drug release 
(Kim and Lee, 1992; Lee and Kim, 1991). 
 
3.2 Plasticized partially hydrolyzed PVOH 
Based on their ability to solubilize HCT in an HME-processed matrix in combination with their 
pH and ionic strength independent drug release PVOH polymers with high degree of 
hydroxylation (> 70%) were promising carriers for HME applications. However, the higher 
temperature required for HME (180°C) of these PVOH samples (type 505 and 4-88) due to 
their semi-crystalline nature hampered their use as carriers for thermosensitive drugs (i.e. 
CEL) (Sovizi, 2010). Therefore, the addition of a plasticizer was evaluated to broaden the 
application of PVOH for HME. The most commonly used plasticizers for PVOH were polyols 
(i.e. polyethylene glycol, glycerol, sorbitol), where hydrogen bonding between the polyols and 
PVOH reduced inter- and intra-molecular hydrogen bonding in the PVOH polymer chains 
(Wu et al., 2012). Sorbitol was selected as low molecular weight and water-soluble 
plasticizer, because sorbitol as solid plasticizer easily could be homogenized and processed 
during HME. 
Whereas no effect of sorbitol (in a concentration up to 40%) during the 1st DSC heating cycle 
was observed, a lower Tg and Tm were detected during the second heating cycle of all 
samples (Table 2). This indicated that the melting of the sorbitol/PVOH mixtures was 
required to establish molecular interactions between the polymer and sorbitol, thus affecting 
the thermal properties of the formulations via the plasticizing effect of sorbitol on the PVOH 
polymer. The effect of sorbitol was linked to its concentration as more interactions can be 
established between the OH-groups of both components, thus disrupting the structural 
regularity of PVOH (Mohsin et al., 2011). Sorbitol concentration was limited to 40% as a 
higher concentration in the PVOH/sorbitol mixture yielded a liquefied mass after extrusion. 
Sorbitol also had a more pronounced impact on PVOH with the highest degree of 
hydroxylation (type 4-88) as more intramolecular interactions can be destroyed due to the 
addition of sorbitol. 
The effect of sorbitol on the thermal properties during DSC was also reflected in the HME 
behavior of the sorbitol/PVOH mixtures. Whereas an extrusion temperature of 180°C was 
required to process physical mixtures of PVOH and sorbitol (i.e. similar condition as for HME-
processing of pure PVOH grades with a high degree of hydroxylation), re-extrusion of 
PVOH/sorbitol mixture (after quench-cooling and cryomilling) required a lower temperature 
for efficient extrusion at low torque: 160°C for mixtures containing 10-30% sorbitol and 140°C 
with 40% sorbitol. There was no difference in extrusion temperature between mixtures 
containing PVOH type 505 (72-75%) or 4-88 (88%). Moisture content of the cryomilled 
material was similar to unmilled PVOH/sorbitol mixtures, thus water sorption during 
cryomilling did not contribute to the observed lower extrusion temperature for the cryomilled 
PVOH/sorbitol formulations.  
Combining the cryomilled plasticized PVOH grades (containing 40% sorbitol) with 15 % CEL 
(melting point 160.6 °C) also allowed HME processing at 140°C. Under these conditions both 
PVOH matrices (type 505 and 4-88) were able to solubilize the entire CEL fraction as 
confirmed by the XRD patterns (Fig. 7) and DSC analysis (Fig. 8). FTIR spectroscopy (Fig. 9) 
showed characteristic peaks of CEL at 3331.4 and 3225.8 cm-1, which corresponded to N-H 
stretching in the SO2NH2 group. While those bands were clearly visible in the physical 
mixture (PM), they broadened after extrusion (EX), likely due to hydrogen bonding between 
the acidic hydrogen of N-H as hydrogen donor from CEL and O-H as hydrogen acceptor of 
PVOH (Fouad et al., 2011). This resulted in a fast release of CEL from the PVOH mixtures 
(Fig. 10). It is important to note that these dissolution tests were performed under non-sink 
conditions in 0.1N HCl and that the CEL/PVOH/sorbitol system was able to maintain 
supersaturation during the length of the dissolution test. In contrast, CEL release from the 
commercially available formulation (Celebrex®) was much slower in the medium and was 
equivalent to the maximum solubility of CEL in 0.1N HCl (3 mg/L). PVOH has already been 
reported as a precipitation inhibitor, able to stabilize supersaturation of drugs (caffeine (Gift 
et al., 2008), danazol (Warren et al., 2010), estradiol (Megrab et al., 1995) and tacrolimus 
(Overhoff et al., 2008)) via drug/polymer interactions. In addition to the lower extrusion 
temperature of this formulation during HME, this could be an important feature to improve the 
bioavailability of solubility-limited drugs (BSC class II). 
The influence of in vitro supersaturation on in vivo bioavailability was investigated after oral 
administration of the formulations to dogs (Fig. 11). Despite the significant differences of the 
in vitro release profiles, all pharmacokinetic parameters were equally good, as cryomilled 
plasticized PVOH (containing 40% sorbitol) with 15% CEL was able to obtain the same 
bioavailability as the reference, which was Celebrex®, a commercially available formulation 
(Table 3). This discrepancy between in vitro and in vivo behavior could be due to the fact that 
in vitro dissolution was limited by the solubility of CEL combined with the fixed volume of 
dissolution media available. In contrast, following in vivo administration sink conditions are 
more likely based on the high permeability of CEL, whereby the rate-limiting factor was 
shifted to its dissolution rate. Therefore, a number of reasons could influence in vivo 
dissolution rate, such as incomplete dissolution of the PVOH carrier, rapid in-vivo diffusion of 
the PVOH polymers after dissolution (making CEL more prone to precipitation)… 
Furthermore, in vivo dissolution of hydrophobic compounds such as CEL (log P = 3.5) could 
be influenced by presence of endogenous compounds (e.g. lecithin), which are able to form 
micelles, and improve solubility (Shono et al., 2009). However, this study emphasize that 
caution needs to be taken for in-vitro/in-vivo correlations. 
 
 
 
 
 
 
 
 
 
 
 
4 CONCLUSIONS 
PVOH polymers were identified as carriers for HME applications, as PVOH with high degree 
of hydrolysis were able to solubilize HCT and CEL up to 15%. The fastest drug release was 
obtained from PVOH formulations with a high degree of hydroxylation, whereby drug release 
was independent of pH (1 – 9) and ionic strength (0 – 0.14M). However, high extrusion 
temperatures were required which could hamper its application for thermosensitive drugs. 
Therefore, PVOH was plasticized with sorbitol, which lowered the extrusion temperature to 
140°C. The in vitro dissolution profiles of CEL were significantly improved, as CEL was in a 
state of supersaturation, and moreover PVOH was able to stabilize supersaturation for at 
least 2h. However, the enhanced in vitro dissolution was not reflected in the in vivo 
bioavailability.  
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Figures 
Fig. 1. MDSC-profiles (total, reversed and non reversed heat flow) of polyvinyl alcohol with 
different degree 
of 
hydrolysis 
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Fig. 2. XRD-profiles of the different polyvinyl alcohol grades 
 
 
 
 
Fig. 3. XRD-profiles of hot-melt extruded formulations containing different grades of polyvinyl 
alcohol in combination with hydrochlorothiazide (ratio: 85/15) 
 
 
 
 
 
Fig. 4. Dissolution profiles (n=3) of hot-melt extruded formulations containing different grades 
of polyvinyl alcohol in combination with hydrochlorothiazide (ratio: 85/15) in function of the 
pH of the dissolution medium (pH 1 (); pH 4.5 (); pH 9 (Δ)). Ionic strength of all dissolution 
media was 0.14M 
 
 
 
 
Fig. 5. Dissolution profiles (n=3) of hot-melt extruded formulations containing different grades 
of polyvinyl alcohol in combination with hydrochlorothiazide (ratio: 85/15) in function of ionic 
strength of the dissolution medium (0 M (); 0.018 M (); 0.089 M (Δ); 0.14 M (). pH of all 
dissolution media was 7.4 
  
 
 
Fig. 6. Dissolution profiles (n=3) of hot-melt extruded formulation containing polyvinyl alcohol 
type 4-88 (88%) and hydrochlorothiazide in 0.1 N HCl in function of hydrochlorothiazide 
concentration: 5% (), 10% (), 15% (Δ) 
  
 
 
Fig. 7. XRD-profile of celecoxib (A), and physical mixture (B) or extrudate (C) containing 
plasticized polyvinyl alcohol type 505 (72-75%) (left) or type 4-88 (88%) (right) and celecoxib 
(15%) 
 
 
 
Fig. 8. DSC-profile of celecoxib (A), and physical mixture (B) or extrudate (C) containing 
plasticized polyvinyl alcohol type 505 (72-75%) (left) or type 4-88 (88%) (right) and celecoxib 
(15%) 
 
 
 
Fig. 9. FTIR spectra of physical mixture (PM) or extrudate (EX) both containing 15% 
celecoxib and pure compounds (polyvinyl alcohol type 505 (72-75%), sorbitol and celecoxib) 
 
 
Fig. 10. Dissolution profiles (n=3) of Celebrex® () and hot-melt extruded formulation 
containing plasticized polyvinyl alcohol type 505 (72-75%) (left) or type 4-88 (88%) (right) () 
in capsules containing 15 mg celecoxib in 0.1N HCl pH 1 
 
 
 
 
Fig. 11. Average plasma concentration vs time profiles of celecoxib (5 mg/kg) after oral 
administration of capsules containing Celebrex® () or the hot-melt extruded formulation 
with polyvinyl alcohol type 505 (72-75%) (Ο) in dogs (n=6) 
 
 
 
 
  
 
 
 
Tables 
 
 
Table 1. General properties and thermal behavior (DSC, using a cooling/heating rate of 
10°C/min) of the four different types of polyvinyl alcohol 
GENERAL PROPERTIES THERMAL BEHAVIOR 
Type %OH 
Mw 
(g/mol) 
1
st
 HEATING 2
nd
 HEATING 
Tg (°C) Tm (°C) Tg (°C) Tm (°C) 
LM 25 33 – 38 48991 38.6 - 44.6 - 
LM 22 47 – 53 47835 40.1 - 48.7 - 
505 72 -75 126543 46.2 154.3 60.8 142.7 
4-88
 
88 92881 45.7 162.3 67.0 143.6 
 
 
 
 
Table 2. Thermal behavior of polyvinyl alcohol/sorbitol mixtures as a function of sorbitol 
concentration, using a cooling/heating rate of 10°C/min 
 1
st
 HEATING 2
nd
 HEATING 
Type 
PVOH 
Sorbitol 
% (m/m) 
Tg 
(°C) 
Tm (onset) 
(°C) 
Tg 
(°C) 
Tm (onset) 
(°C) 
505 0 46.2 154.3 60.8 142.7 
(72/75%) 10 46.3 150.7 57.7 142.1 
20 46.1 153.3 50.9 136.6 
30 46.2 148.5 41.0 131.2 
40 46.8 169.5 35.4 123.1 
4-88 
(88%) 
0 45.7 162.3 67.0 143.6 
10 48.0 161.5 52.9 134.5 
20 46.8 160.1 37.1 128.9 
30 46.1 132.1 13.7 126.9 
40 40.0 138.6 13.1 126.4 
 
 
 
 
 
Table 3. Pharmacokinetic parameters of celecoxib (5 mg/kg) after oral administration of 
capsules containing Celebrex® or the hot-melt extruded formulation with polyvinyl alcohol 
type 505 in dogs (n=6) 
 Celebrex® PVOH type 505 (72-75%) 
AUC0-24h (ng.h/ml) 9869.3 ± 4508.3 10176.2 ± 4188.2 
Cmax (ng/ml) 1035.8 ± 336.8 1000.2 ± 193.7 
Tmax (h) 3.5 ± 1.5 3.0 ± 1.9 
Rel. bioavailability F (%)  96.6 
 
 
 
 
